1
|
Gutierrez-Rivas E. [How we, as neurologists, write. Reply]. Rev Neurol 2016; 62:528. [PMID: 27222089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
|
2
|
Querol L, Rojas-Garcia R, Casasnovas C, Sedano MJ, Muñoz-Blanco JL, Alberti MA, Paradas C, Sevilla T, Pardo J, Capablo JL, Sivera R, Guerrero A, Gutierrez-Rivas E, Illa I. Long-term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: A retrospective study. Muscle Nerve 2013; 48:870-6. [DOI: 10.1002/mus.23843] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/11/2013] [Indexed: 11/08/2022]
Affiliation(s)
- Luis Querol
- Neuromuscular Diseases Department; Hospital de la Santa Creu i Sant Pau; Mas Casanovas 90 08041 Barcelona Spain
- Centro Investigacion Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED); Madrid Spain
| | - Ricard Rojas-Garcia
- Neuromuscular Diseases Department; Hospital de la Santa Creu i Sant Pau; Mas Casanovas 90 08041 Barcelona Spain
- Centro Investigacion Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED); Madrid Spain
| | - Carlos Casasnovas
- Centro Investigacion Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED); Madrid Spain
- Neuromuscular Diseases Unit; Hospital Universitari de Bellvitge; Barcelona Spain
| | - Maria Jose Sedano
- Neurology Department; Hospital Universitario “Marques de Valdecilla”; Santander Spain
| | - Jose Luis Muñoz-Blanco
- Centro Investigacion Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED); Madrid Spain
- Neuromuscular Diseases and ALS Unit; Hospital Universitario Gregorio Marañón; Madrid Spain
| | | | - Carmen Paradas
- Centro Investigacion Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED); Madrid Spain
- Neuromuscular Diseases Unit; Hospital Universitario Virgen del Rocío; Sevilla Spain
| | - Teresa Sevilla
- Neurology Department; Hospital Universitari I Politècnic La Fe; Valencia Spain
| | - Julio Pardo
- Centro Investigacion Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED); Madrid Spain
- Neurology Department; Hospital Universitario de Santiago; Santiago de Compostela Spain
| | - Jose Luis Capablo
- Neurology Department; Hospital Universitario “Miguel Servet”; Zaragoza Spain
| | - Rafael Sivera
- Neurology Department; Hospital Universitari I Politècnic La Fe; Valencia Spain
| | - Antonio Guerrero
- Centro Investigacion Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED); Madrid Spain
- Neuromuscular Diseases and ALS Unit; Hospital Clinico “San Carlos”; Madrid Spain
| | | | - Isabel Illa
- Neuromuscular Diseases Department; Hospital de la Santa Creu i Sant Pau; Mas Casanovas 90 08041 Barcelona Spain
- Centro Investigacion Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED); Madrid Spain
| |
Collapse
|
3
|
Barba-Romero MA, Barrot E, Bautista-Lorite J, Gutierrez-Rivas E, Illa I, Jimenez LM, Ley-Martos M, Lopez de Munain A, Pardo J, Pascual-Pascual SI, Perez-Lopez J, Solera J, Vilchez-Padilla JJ. Clinical guidelines for late-onset Pompe disease. Rev Neurol 2012; 54:497-507. [PMID: 22492103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Before 2006, Pompe disease or glycogenosis storage disease type II was an incurable disease whose treatment was merely palliative. The development of a recombinant human alpha-glucosidase enzymatic replacement therapy has become the first specific treatment for this illness. The aim of this guide is to serve as reference for the management of the late-onset Pompe disease, the type of Pompe disease that develops after one year of age. In the guide a group of Spanish experts make specific recommendations about diagnosis, follow-up and treatment of this illness. With regard to diagnosis, the dried blood spots method is essential as the first step for the diagnosis of Pompe disease. The confirmation of the diagnosis of Pompe disease must be made by means of an study of enzymatic activity in isolated lymphocytes or a mutation analysis of the alpha-glucosidase gene. With regard to treatment with enzymatic replacement therapy, the experts say that is effective improving or stabilizating the motor function and the respiratory function and it must be introduced when the first symptoms attributable to Pompe disease appear.
Collapse
Affiliation(s)
- M A Barba-Romero
- Department of Internal Medicine, Hospital General Universitario de Albacete, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Verdura E, Gonzalez-Quereda L, Juan-Mateu J, Rodriguez M, Cabello A, Castro Gago M, Coll J, Colomer J, Gutierrez-Rivas E, Hankiewicz K, Lopez de Munain A, Navarro C, Pascual S, Pou A, Ramos M, Vidal Ríos P, Baiget M, Gallano P. P2.34 Mutational spectrum of sarcoglycanopathies in Spain. Neuromuscul Disord 2011. [DOI: 10.1016/j.nmd.2011.06.856] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
5
|
De Andres I, Gutierrez-Rivas E, Nava E, Reinoso-Suarez F. Independence of sleep-wakefulness cycle in an implanted head 'encephale isole'. Neurosci Lett 2009; 2:13-8. [PMID: 19604806 DOI: 10.1016/0304-3940(76)90038-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/1976] [Accepted: 01/29/1976] [Indexed: 10/27/2022]
Abstract
A quantitative study was carried out on the sleep-wakefulness cycle by means of EEG recordings taken simultaneously from a dog's implanted head and its host. During survival (108 h), neurological activities of the implanted head were similar to those of classic 'encéphale isolé' preparations. In spite of a common circulation, the sleep-wakefulness cycles of the implanted head and host animal were independent. Independence was manifested by: (1) differing percentages of respective phases of their cycles; (2) periods of coincident phases in both heads, only occasionally beginning and/or stopping simultaneously; and (3) the implanted 'encéphale isolé' showed a monotonous cycle with numerous periods of short duration throughout night or day. The host presented a nycthemeral rhythm.
Collapse
Affiliation(s)
- I De Andres
- Departamento de Morfología, Facultad de Medicina, Universidad Autónoma de Madrid, Spain
| | | | | | | |
Collapse
|
6
|
Blázquez L, Azpitarte M, Sáenz A, Goicoechea M, Otaegui D, Ferrer X, Illa I, Gutierrez-Rivas E, Vilchez JJ, López de Munain A. Characterization of novel CAPN3 isoforms in white blood cells: an alternative approach for limb-girdle muscular dystrophy 2A diagnosis. Neurogenetics 2008; 9:173-82. [PMID: 18563459 DOI: 10.1007/s10048-008-0129-1] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2007] [Accepted: 03/26/2008] [Indexed: 10/21/2022]
Abstract
Limb-girdle muscular dystrophy type 2A (LGMD2A) is an autosomal recessive disorder caused by mutations in the CAPN3 gene. Its definitive diagnosis is laborious, since the clinical phenotype is often similar to other types of muscular dystrophy and since the CAPN3 gene encompasses a large genomic region with more than 300 pathogenic mutations described to date. In fact, it is estimated that nearly 25% of the cases with a phenotype suggestive of LGMD2A do not have mutations in the CAPN3 gene and that, in up to 22% of the cases, only one mutation is identified. In the present work, we have characterised CAPN3 messenger RNA (mRNA) expression in peripheral blood, and we have performed a retrospective diagnostic study with 26 LGMD2A patients, sequencing a transcript of CAPN3 present in white blood cells (WBCs). The 25% of the mutations presented in this paper (7/28) act modifying pre-mRNA splicing of the CAPN3 transcript, including the first deep-intronic mutation described to date in the CAPN3 gene. Our results determine that the sequencing of CAPN3 transcripts present in WBCs could be applied as a new approach for LGMD2A diagnosis. This method improves and simplifies diagnosis, since it combines the advantages of mRNA analysis in a more accessible and rapidly regenerated tissue. However, the lack of exon 15 in the CAPN3 isoforms present in blood, and the presence of mRNA degradation make it necessary to combine mRNA and DNA analyses in some specific cases.
Collapse
Affiliation(s)
- L Blázquez
- Experimental Unit, Hospital Donostia, San Sebastián, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Gomez-Moreno M, Carnal-Martin P, Camaño P, Alonso-Ortiz A, Gutierrez-Rivas E. G.P.7.01 Facioscapulohumeral muscular dystrophy: A review of 76 patients. Neuromuscul Disord 2007. [DOI: 10.1016/j.nmd.2007.06.152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
8
|
Blázquez L, Azpitarte M, Goicoechea M, Sáenz A, Zuriarrain O, Vilchez J, Illa I, Ferrer X, Gutierrez-Rivas E, López de Munain A. G.P.4.16 Characterization of calpain 3 expression in white blood cells and its application as a diagnostic tool in LGMD2A. Neuromuscul Disord 2007. [DOI: 10.1016/j.nmd.2007.06.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
9
|
Berbel-Garcia A, Barbera-Farre JR, Etessam JP, Salio AM, Cabello A, Gutierrez-Rivas E, Campos Y. Coenzyme Q 10 Improves Lactic Acidosis, Strokelike Episodes, and Epilepsy in a Patient With MELAS (Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Strokelike episodes). Clin Neuropharmacol 2004; 27:187-91. [PMID: 15319706 DOI: 10.1097/01.wnf.0000137862.67131.bf] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Mitochondrial encephalomyopathies encompass a group of disorders that have impaired oxidative metabolism in skeletal muscles and central nervous system. Many compounds have been used in clinical trials on mitochondrial diseases, but the outcomes have been variable. It remains controversial whether treatment of mitochondrial diseases with coenzyme Q 10 is effective. This paper describes a case of mitochondrial myopathy, encephalopathy, lactic acidosis, strokelike episodes, and exercise intolerance successfully treated with coenzyme Q 10. Efficacy of this therapy in this patient is correlated to control of lactic acidosis and serum creatine kinase levels. Disappointingly, larger studies with coenzyme Q 10 failed to demonstrate a clear beneficial effect on the entire study population with regard to clinical improvement or several parameters of the oxidative metabolism. They suggest that the use of coenzyme Q in treatment of mitochondrial diseases should be confined to protocols. There is a confounding variation in phenotype and genotype, and the natural history of the disorders in individual patients is not accurately predictable. The unpredictable a priori efficacy of therapy suggests that a long-term trial of oral coenzyme Q may be warranted.
Collapse
Affiliation(s)
- Angel Berbel-Garcia
- Department of Neurology, Hospital Mancha Centro, Alcazar de San Juan, Ciudad Real, Spain.
| | | | | | | | | | | | | |
Collapse
|
10
|
Campos Y, Bautista J, Gutierrez-Rivas E, Llabrés J, Lorenzo G, Arenas J. Variable clinical expression associated with the mutation 3243 np of mitochondrial DNA. J Inherit Metab Dis 1994; 17:634-5. [PMID: 7837776 DOI: 10.1007/bf00711608] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
- Y Campos
- Centro de Investigación, Hospital 12 de Octubre, Madrid, Spain
| | | | | | | | | | | |
Collapse
|
11
|
Barroso N, Campos Y, Huertas R, Esteban J, Molina JA, Alonso A, Gutierrez-Rivas E, Arenas J. Respiratory chain enzyme activities in lymphocytes from untreated patients with Parkinson disease. Clin Chem 1993. [DOI: 10.1093/clinchem/39.4.667] [Citation(s) in RCA: 60] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Respiratory chain enzyme activities were studied in lymphocytes from patients with Parkinson disease (PD) (n = 16) and age-matched control subjects (n = 15). The patients had received no therapy before the study was conducted. Complex I, III, and IV activities were significantly lower (P < 0.05) in patients than in control subjects. A complex I defect was found in one patient, whereas complex IV was defective in another. Two patients had combined defects of both complexes. The use of lymphocytes for investigating the respiratory chain enzymes provides an easy, noninvasive method to assess mitochondrial function in patients with PD. Furthermore, our study supports the hypothesis that a biochemical defect in the respiratory chain may be involved in the pathogenesis of PD.
Collapse
Affiliation(s)
- N Barroso
- Servicio de Bioquímica, Hospital 12 de Octubre, Madrid, Spain
| | - Y Campos
- Servicio de Bioquímica, Hospital 12 de Octubre, Madrid, Spain
| | - R Huertas
- Servicio de Bioquímica, Hospital 12 de Octubre, Madrid, Spain
| | - J Esteban
- Servicio de Bioquímica, Hospital 12 de Octubre, Madrid, Spain
| | - J A Molina
- Servicio de Bioquímica, Hospital 12 de Octubre, Madrid, Spain
| | - A Alonso
- Servicio de Bioquímica, Hospital 12 de Octubre, Madrid, Spain
| | | | - J Arenas
- Servicio de Bioquímica, Hospital 12 de Octubre, Madrid, Spain
| |
Collapse
|
12
|
Barroso N, Campos Y, Huertas R, Esteban J, Molina JA, Alonso A, Gutierrez-Rivas E, Arenas J. Respiratory chain enzyme activities in lymphocytes from untreated patients with Parkinson disease. Clin Chem 1993; 39:667-9. [PMID: 8386068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Respiratory chain enzyme activities were studied in lymphocytes from patients with Parkinson disease (PD) (n = 16) and age-matched control subjects (n = 15). The patients had received no therapy before the study was conducted. Complex I, III, and IV activities were significantly lower (P < 0.05) in patients than in control subjects. A complex I defect was found in one patient, whereas complex IV was defective in another. Two patients had combined defects of both complexes. The use of lymphocytes for investigating the respiratory chain enzymes provides an easy, noninvasive method to assess mitochondrial function in patients with PD. Furthermore, our study supports the hypothesis that a biochemical defect in the respiratory chain may be involved in the pathogenesis of PD.
Collapse
Affiliation(s)
- N Barroso
- Servicio de Bioquímica, Hospital 12 de Octubre, Madrid, Spain
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Lahuerta-Palacios J, Fernandez-Debora F, Ortiz-Conde MC, Larregla S, Gutierrez-Rivas E. Rapid control of myeloid compartment with vindesine in chronic phase of chronic myelogenous leukemia. Cancer Treat Rep 1986; 70:315-6. [PMID: 3456274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|